Plaque Psoriasis Clinical Trials

• Participants must have stable plaque psoriasis for 6 months or more prior to Screening.

• Participants must have moderate to severe psoriasis defined by:.

• i) Psoriasis Area and Severity Index (PASI) ≥ 12, at screening visit and Day 1.

⁃ ii) Static Physician's Global Assessment (sPGA) ≥ 3, at screening visit and Day 1.

⁃ iii) Body Surface Area (BSA) ≥ 10% involvement, at screening visit and Day 1.

⁃ \- A female (as assigned at birth) participant is eligible to participate if she is not pregnant or breastfeeding, and at least 1 of the following conditions applies:.

⁃ i) Is not an individual of childbearing potential (IOCBP).

⁃ ii) Is an IOCBP and using a contraceptive method that is highly effective (with a failure rate of \< 1% per year) during the study intervention period and for at least 3 days after discontinuation of the study intervention and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction for the same period.